SEC Comment Letter 0000000000-24-001944 to WINDTREE THERAPEUTICS INC /DE/ (WINT)
WINDTREE THERAPEUTICS INC /DE/
Date: Feb. 20, 2024 · CIK: 0000946486 · Accession: 0000000000-24-001944
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277073
Letter
United States securities and exchange commission logo February 20, 2024 Craig Fraser Chief Executive Officer Wintertree Therapeutics, Inc. 2600 Kelly Road, Suite 100 Warrington, PA 18976 Re:Wintertree Therapeutics, Inc. Registration Statement on Form S-3 Filed February 14, 2024 File No. 333-277073 Dear Craig Fraser: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Justin Platt, Esq.
Show Raw Text
United States securities and exchange commission logo
February 20, 2024
Craig Fraser
Chief Executive Officer
Wintertree Therapeutics, Inc.
2600 Kelly Road, Suite 100
Warrington, PA 18976
Re:Wintertree Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 14, 2024
File No. 333-277073
Dear Craig Fraser:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Justin Platt, Esq.